drugset / Trial / NCT00637286
ZAP, US. Zomig for Appropriate for Primary Care
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine how useful and effective the use of ZOMIG-ZMT™ (zolmitriptan) 5.0 mg and ZOMIG® Nasal Spray (zolmitriptan) 5.0 mg is for patients, in treating migraine over a period of 6 months
Timeline
- Start
- 2004-07
- Primary completion
- —
- Completion
- 2005-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Zolmitriptan | Small molecule | 5 mg | Intranasal |